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Introduction
Patients surviving episodes of acute kidney injury 
(AKI) can recover their renal function without fur-
ther consequences for many years. However, recent 
evidence based on epidemiological investigations 
and outcome analyses showed that AKI is a risk 
factor for the development and progression of 
chronic kidney disease (CKD), and, in particular, 
for promoting the transition of CKD to end-stage 
renal disease (ESRD) ultimately requiring dialy-
sis.1–3 AKI and CKD have been seen as an inte-
grated clinical syndrome.4 Hypoxia, inflammation, 
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Abstract
Background: Acute kidney injury (AKI) is one of the major risk factors for progression to 
chronic kidney disease (CKD) and renal fibrosis. However, effective therapies remain poorly 
understood. Here, we examined the renoprotective effects of melatonin and poricoic acid  
A (PAA) isolated from the surface layer of Poria cocos, and investigated the effects of  
combined therapy on the interaction of TGF-β/Smad and Wnt/β-catenin in a rat model of  
renal ischemia-reperfusion injury (IRI) and hypoxia/reoxygenation (H/R) or TGF-β1-induced 
HK-2 cells.
Methods: Western blot and immunohistochemical staining were used to examine protein 
expression, while qRT-PCR was used to examine mRNA expression. Coimmunoprecipitation, 
chromatin immunoprecipitation, RNA interference, and luciferase reporter gene analysis were 
employed to explore the mechanisms of PAA and melatonin’s renoprotective effects.
Results: PAA and combined therapy exhibited renoprotective and antifibrotic effects, but the 
underlying mechanisms were different during AKI-to-CKD continuum. Melatonin suppressed 
Smad-dependent and Smad-independent pathways, while PAA selectively inhibited Smad3 
phosphorylation through distrupting the interactions of Smad3 with TGFβRI and SARA. Further 
studies demonstrated that the inhibitory effects of melatonin and PAA were partially depended 
on Smad3, especially PAA. Melatonin and PAA also inhibited the Wnt/β-catenin pathway and 
its profibrotic downstream targets, and PAA performed better. We further determined that 
IRI induced a nuclear Smad3/β-catenin complex, while melatonin and PAA disturbed the 
interaction of Smad3 and β-catenin, and supplementing with PAA could enhance the inhibitory 
effects of melatonin on the TGF-β/Smad and Wnt/β-catenin pathways.
Conclusions: Combined melatonin and PAA provides a promising therapeutic strategy to treat 
renal fibrosis during the AKI-to-CKD continuum.
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microvascular rarefaction, and dysbiosis of gut 
microbiota have been linked to the AKI-to-CKD 
continuum.2,5,6 Renal ischemia/reperfusion injury 
(IRI) has been used widely to investigate renal 
fibrosis from AKI to progressive CKD.7–10 Renal 
fibrosis is always the common ultimate result of 
CKD, which is characterized by the process of epi-
thelial-to-mesenchymal transition (EMT) and 
excessive accumulation and deposition of extracel-
lular matrix (ECM) components.11 Renal fibrosis is 
induced by the activation of a large number of 
growth factors, cytokines, chemokines and toxins, 
among which transforming growth factor-β1 
(TGF-β1) and β-catenin are the central mediators 
in renal fibrosis.12,13
The TGF-β/Smad and Wnt/β-catenin pathways 
play a significant role in fibrogenesis of the kid-
ney. TGF-β signaling is a central mediator in 
renal fibrosis of progressive CKD.11,14 TGF-β 
exerts its profibrotic effect by transforming growth 
factor-β receptor II (TGFβRII), transforming 
growth factor-β receptor I (TGFβRI), and its 
intracellular mediators Smads. The combination 
of TGF-β1 and TGFβRII recruits and phospho-
rylates TGFβRI, which causes phosphorylation 
of Smad2 and Smad3 via the junction of adaptor 
proteins such as Smad anchor for receptor activa-
tion (SARA).15 The phosphorylations of Smad2 
and Smad3 regulate downstream profibrotic fac-
tor expressions. Smad4 also contributes to TGF-
β1-induced fibrogenesis,16 while Smad7 is a 
negative regulator of the TGF-β/Smad pathway 
by inhibition of Smad2 and Smad3 phosphoryla-
tion.17 In the normal situation, the Wnt/β-catenin 
pathway is silent in adult kidney; once an injury 
occurs, Wnt/β-catenin signaling is reactive.12,15 
Sustained activation of the Wnt/β-catenin path-
way plays a decisive role in driving the AKI-to-
CKD continuum and accelerates renal fibrosis.7 
Profibrotic and fibrotic genes, including snail1, 
twist, plasminogen activator inhibitor-1 (PAI-1), 
fibroblast-specific protein 1 (Fsp-1) and matrix 
metalloproteinase-7 (MMP-7), are the down-
stream targets of Wnt/β-catenin signaling.18 Since 
renin-angiotensin system (RAS) components are 
also directly downstream of Wnt/β-catenin sign-
aling, the activation of Wnt/β-catenin signaling 
could upregulate the expression of RAS compo-
nents to accelerate kidney injury.19 Hence, inhibi-
tion of the TGF-β/Smad and Wnt/β-catenin 
pathways plays a critical role in attenuating renal 
fibrosis.
Although the molecular mechanisms underlying 
the AKI-to-CKD continuum have been partly 
revealed, no intervention has proved very effec-
tive to block the AKI-to-CKD continuum. 
Pharma cologic treatment to block the AKI-to-
CKD continuum is urgently needed. In recent 
years, natural products have shown renoprotec-
tive and antifibrotic effects.20–24 The surface layer 
of Poria Cocos (SLPC) exerts renoprotective 
effects,25–29 and also has antifibrotic effects via 
regulation of the TGF-β/Smad and Wnt/β-
catenin pathways.30,31 Poricoic acid A (PAA), as a 
main triterpenoid compound of SLPC,32 exhibits 
a good antifibrotic effect in vivo and in vitro. 
Additionally, melatonin, a secretory product of 
the pineal gland, has been reported to have antifi-
brotic effect in the kidney.33–35 Although mela-
tonin and PAA significantly alleviate renal 
fibrosis, their underlying mechanism remains 
undefined. In this study, we reveal the molecular 
mechanism of a combined melatonin and PAA 
intervention on the AKI-to-CKD continuum in 
renal IRI rats and hypoxia/reoxygenation (H/R) 
or TGF-β1 induced epithelial cells. Elucidating 
the molecular mechanism of the inhibitory effect 
of melatonin and PAA treatment on the AKI-to-
CKD continuum will support the development of 
therapeutic options to prevent progression from 
AKI to CKD.
Materials and methods
Materials
Melatonin was purchased from Sigma-Aldrich 
(M5250, St. Louis, MO, USA). DMEM/F-12 
and fetal bovine serum were purchased from 
Thermo Fisher Scientific (New York, NY, USA). 
SLPC was purchased from Shaanxi Medicinal 
Materials Company (Xi’an, Shaanxi, China). The 
primary antibodies were purchased from Abcam 
(Cambridge, MA, USA), Millipore (Billerica, 
MA, USA), CST (Danvers, MA, USA), BD 
Transduction Laboratories (San Jose, CA, USA), 
Santa Cruz (Dallas, TX, USA), and Proteintech 
(Wuhan, Hubei, China).
Primary antibodies against collagen I (ab34710, 
Abcam), alpha smooth muscle actin (α-SMA, 
ab7817, Abcam), fibronectin (ab2413, Abcam), 
vimentin (ab92547, Abcam), E-cadherin 
(ab76055, Abcam), Wnt1 (ab85060, Abcam), 
dephosphorylated active β-catenin (05-665, 
D-Q Chen, G Cao et al.
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Millipore), phosphorylated active β-catenin 
(Ser33/37/Thr41) (9561, CST), β-catenin 
(610154, BD Transduction Laboratories), snail1 
(ab180714, Abcam), twist (ab50581, Abcam), 
MMP-7 (ab5706, Abcam), PAI-1 (612024, BD 
Transduction Laboratories), TGF-β1 (ab92486, 
Abcam), TGFβRI (ab31013, Abcam), SARA 
(ab124875, Abcam), p-Smad2 (3180, CST), 
Smad2 (5339, CST), p-Smad3 (9520, CST), 
Smad3 (9523, CST), Smad4 (38454, CST), 
Smad7 (sc-365846, Santa Cruz), p-ERK1/2 
(4370, CST), ERK1/2 (9102, CST), p-p38 (4511, 
CST), p38 (8690, CST), p-PI3K (ab182651, 
Abcam), PI3K (4257, CST), α-tubulin (11224-1-
AP, Proteintech), and β-actin (20536-1-AP, 
Proteintech) were used in the present study. The 
secondary antibodies goat anti-rabbit (A21000) 
and goat anti-mouse (A21010) were purchased 
from Abbkine (California, CA, USA).
Extraction and isolation of PAA
SLPC (20 kg) was powdered and extracted with 
95% EtOH (100 l) three times. The solvent was 
removed under reduced pressure and crude 
extracts were obtained. The crude extracts (830 
g) was subsequently dissolved in water and suc-
cessively partitioned with petroleum ether, 
EtOAC, and n-BuOH to yield three fractions. 
EtOAC fractionation (500 g) was performed on 
MCI gel CHP20P, eluted with a gradient system 
of MeOH-H2O (from 50:50 to 100:0) and yielded 
five fractions, A–F. Fraction C (60 g) was sub-
jected to normal-phase fractionation on silica gel 
column chromatography using CH2Cl2-MeOH 
(from 100:1 to 1:1) and yielded seven fractions, 
C1–C7. Fraction C4 (12.1 g) was purified over 
RP-18 column chromatography using MeOH-
H2O elution system (from 50:50 to 100:0) and 
yielded fractions C41–C43. C42 (6.0 g) was then 
purified by reverse-phase semipreparative HPLC 
applying a MeOH-H2O (85:15) elution system 
and a flow rate of 3 ml/min for 25 min.
Animals and treatment
All protocols concerning the use of animals were 
carried out in accordance with the recommenda-
tions in the Guide for the Care and Use of 
Laboratory Animals of the State Committee of 
Science and Technology of the People’s Republic 
of China, and were approved by the Committee 
on the Ethics of Animal Experiments of the 
Northwest University (Permit Number: 
SYXK2010-004). Male Sprague-Dawley rats 
with an age of 7 weeks old, weighing 180–200 g, 
were purchased from the Central Animal 
Breeding House of Fourth Military Medical 
University (Xi’an, Shaanxi, China). Rats were 
provided with food and water ad libitum, and 
housed in plastic cages (four rats per cage) placed 
in a normal conditioned vivarium with 40–70% 
humidity at 22 ± 2°C and 12 h light/12 h 
dark cycle. Rats were acclimated to their housing 
environment for 7 days prior to experimentation, 
and to the experimental room for 1 h before 
experiments. Animal studies are reported in 
compliance with ARRIVE guidelines. Rats were 
divided randomly into five groups (n = 7 each): 
(1) sham, (2) IRI, (3) IRI + melatonin, (4) IRI  
+ PAA, and (5) IRI + melatonin + PAA group. 
After being anesthetized with chloral hydrate by 
intraperitoneal injection (10%, 10 ml/ kg), IRI 
rats were induced by clamping the bilateral renal 
pedicles for 1 h using a nontraumatic bulldog 
clamp. Sham rats received laparotomy only. 
After reperfusion, rats were given melatonin at a 
dose of 20 mg/kg by intraperitoneal injection at 
30 min and 50 mg/kg at 6 h and 18 h. In addi-
tion, melatonin (50 mg/kg) was given by intra-
peritoneal injection from day 1 to day 7 after 
reperfusion in the morning. PAA (10 mg/kg) was 
given by gavage from day 1 to day 14 after reper-
fusion in the morning. Under general anaesthe-
sia, all rats were sacrificed at the end of the 2nd 
week in the morning. The ligated kidneys were 
separated into two parts. One was immediately 
frozen and saved in liquid nitrogen for western 
blot and qRT-PCR analyses, and the other was 
used for immumohistochemical staining to inves-
tigate the therapeutic effects of melatonin and 
PAA against renal fibrosis.
Cell culture and treatment
HK-2 cells were cultured in DMEM-F12 supple-
mented with 10% fetal bovine serum with 5% 
CO2 at 37°C. HK-2 cells were divided into seven 
groups (n = 5): control (CTL), melatonin 
(MEL), PAA, H/R, H/R + melatonin (H/R + 
MEL), H/R + PAA, and H/R + melatonin + 
PAA (H/R + MEL + PAA). H/R cells were 
placed in a hypoxic chamber under 0% O2 atmos-
phere for 6 h, and then placed under normal con-
ditions for reoxygenation for 12 h. During 
reoxygenation, the treated groups were incubated 
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with melatonin (10 μM) and PAA (10 μM). 
Additonally, TGF-β (2.5 ng/ml) was also used to 
stimulate HK-2 cells
Lentivirus expressing full-length human Wnt1 
cDNA (Wnt1 over) was constructed by Sangon 
(Shanghai, China). Lipofectamine 3000 was used 
according to the manufacturer’s guide.
Knockdown of Smad3 by small interfering RNA
Specific Smad3 small interfering RNA (siRNA) 
(5'-CCGCAUGAGCUUCGUCAAATT-3') or 
control siRNA (CTL siRNA) (5'-UUCUCCG 
AACGUGUCACGUTT-3') was synthesized by 
Sangon (Guangzhou, Guangdong, China). HK-2 
cells were cultured in six-well plates and transfected 
with 3 μl of 10 μM siRNA/well by using 9 μl lipo-
fectamine RNAiMAX (Invitrogen, New York, NY, 
USA). After incubation for 48 h, the HK-2 cells 
were used for subsequent experiments.
Histology and immunohistochemical staining
Kidney tissues were fixed in 4% paraformalde-
hyde overnight, subsequently processed for paraf-
fin embedding, then sectioned at 5 μm. Kidney 
sections were deparaffinized and hydrated 
through a graded ethanol series, then stained with 
periodic acid–Schiff (PAS) reagent using a stand-
ard protocol.19 Immunohistochemical staining 
was performed using a routine protocol.36
Immunofluorescence staining and confocal 
microscopy
HK-2 cells were cultured on coverslips and fixed 
with 4% paraformaldehyde for 10 min. After 
blocking with 10% goat serum for 30 min, the 
cells were immunostained with primary antibod-
ies at 4°C overnight. After washing three times 
with PBS, cells were incubated with the corre-
sponding secondary antibodies for 2 h at room 
temperature. The cells were mounted with 80% 
glycerinum in PBS and subsequently examined 
by a laser-scanning confocal microscope (FV1000, 
Olympus Corporation, Tokyo, Japan) equipped 
with FV10-ASW 4.0 VIEW.
Protein extraction and Western blotting analysis
Kidney tissues and cells were lysed in RIPA buffer 
and protein concentrations were measured with a 
Pierce™ BCA Protein Assay Kit (23227, Thermo 
Scientific, New York, NY, USA). Standard west-
ern blots were performed. Briefly, 20–30 μg of 
protein was separated by 8–12% SDS-PAGE gel 
and transferred to PVDF membranes. After 
blocking in 5% nonfat milk buffer, blots were 
probed with primary antibodies. After incubation 
with corresponding secondary antibodies, immu-
noblots were visualized by Amersham ECL prime 
western blotting detection reagent (RPN2232, 
GE Healthcare, New York, NY, USA). Signal 
intensities were quantified with ImageJ software 
(version 1.48 v, NIH, Bethesda, MD, USA). α-
Tubulin or β-actin was used as a loading control. 
Quantification of each protein was repeated three 
times.
Quantitative real-time PCR
Total mRNA was extracted with Trizol reagent 
(Invitrogen). The mRNA (0.5 μg) was used to 
synthesize cDNA using a Transcriptor First 
Strand cDNA Synthesis Kit (Roche, Mannheim, 
Germany). Quantitative real-time PCR (qRT-
PCR) was conducted using SYBR® Premix Ex 
Taq™ II (Takara Bio, Otsu, Shiga, Japan). The 
primer sequences are listed in Table 1. Samples 
were amplified for 40 cycles using a Bio-Rad 
CFX 96 Touch™ system (Bio-Rad, Hercules, 
CA, USA). mRNA levels, normalized to GAPDH 
(human) or β-actin (rat), were determined using 
the comparative ΔΔCt method.12
Coimmunoprecipitation
The interactions of Smad2 or Smad3 with 
TGFβRI and SARA were determined by coim-
munoprecipitation (Co-IP). After pretreatment 
with protein A/G (Immunoprecipitation Starter 
Pack, GE Healthcare, NY, New York, USA) for 
1 h at 4°C to remove antibodies present in lysates, 
supernatants were transferred into a fresh 
Eppendorf tube. The supernatants were incu-
bated with anti-TGFβRI (1:50) or SARA anti-
body (1:50) overnight at 4°C to couple antigen to 
antibody, and then immunoprecipitated by pro-
tein A/G to precipitate the immune complexes. 
After washing three times with lysis buffer, the 
supernatants were boiled for 3 min in sample 
buffer.
To investigate the interaction of Smad3 and 
β-catenin in the nucleus, nucleoprotein was 
extracted using NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (78835, Thermo Scientific, 
D-Q Chen, G Cao et al.
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New York, NY, USA), using anti-β-catenin anti-
body (1:100).
Chromatin immunoprecipitation assay
β-Catenin protein complex binding to chromo-
somal DNA was evaluated in rats and HK-2 cells 
by chromatin immunoprecipitation (ChIP) assay. 
The ChIP assay was carried out using a Pierce 
Agarose ChIP Kit (26156, New York, NY, USA) 
according to the manufacturer’s instructions. 
DNA/protein complexes were crosslinked for 10 
min in formaldehyde (28906, New York, NY, 
USA) at a final concentration of 1%. The fixed 
kidney tissues or cells were lysed to obtain nuclei. 
Chromatin was digested by employing micrococ-
cal nuclease at 4°C for 5 min. For immunopre-
cipitation, cell lysates were incubated with an 
antibody against β-catenin (3 μg) and incubated 
overnight at 4°C on a rocking platform, while 
immunoprecipitation with normal rabbit IgG was 
used as a control. The immunoprecipitations were 
subjected to qRT-PCR with primer sets that 
amplify angiotensinogen (AGT), renin, angioten-
sin-converting enzyme (ACE), angiotensin II type 
1 receptor (AT1R), snail1, twist, PAI-1, and 
MMP–7. Primers for ChIP were designed and 
synthesized by Sangon (Guangzhou, Guangdong, 
China). The primer sequences are listed in Table 
2. Fold-enrichment relative to the IgG antibody 
control (negative control) set to 1.0 was calculated 
using the comparative CT method (ΔΔCt).
Smad3-dependent promoter assay
HK-2 cells were transfected with the Smad3-
responsive promoter p(GAGA)12-luc as previously 
described.37 Lipofectamine 3000 (Invitrogen, 
New York, NY, USA) was employed to perform 
the transfection according to the manufacturer’s 
instructions. After transfection, HK-2 cells were 
treated as indicated. Luciferase activity was 
analyzed by a luciferase reporter gene assay kit 
(Roche, Mannheim, Germany) according to the 
manufacturer’s instructions, and normalized by 
protein concentration.
Table 1. Nucleotide sequences of the primers used for qRT-PCR.
Gene Forward Reverse Product size (bp)
Rat  
Wnt1 CATCGTGAACATAGCCTCCTC ATCAGTCGTCGCTGCTTG 108
Wnt2 GCCTTTGTTTACGCCATCTC GATCGCAGGAACAGGACTTTA 91
Wnt3 GCAAATGCCATGGGTTGTC CGTACTTGTCCTTGAGGAAGTC 99
Wnt3a TGCAAATGCCACGGACTAT GGTGTTTCTCTACCACCATCTC 133
Wnt7a GATCCTGGAGGAGAACATGAAA GTAGCCTAGCTCTCGGAATTG 109
Wnt8a CATGTACGCTGTCACCAAGA CCACCTGCTTTCCCATTATTTG 84
β-actin GTGCCCATCTATGAGGGTTATG GCTGTGGTCACGAAGGAATAG 125
Human  
Wnt1 CTGGCTGGGTTTCTGCTAC GAGGAGGCTACGTTCACAATAC 106
Wnt2 CTCCTCAGCTGGAGTTGTATTT GGCGCTTCCCATCTTCTT 94
Wnt3 GGCTGTGACTCGCATCATAA GAACTCCCTGGACACTAACAC 99
Wnt3a TGTTGGGCCACAGTATTCC GGCATGATCTCCACGTAGTT 111
Wnt7a CGTTCACCTACGCCATCATT GTACTGGCCTTGCTTCTCTTT 110
Wnt8a CAGTGAGAGCCACCATGAAA CCTGGTCATACTTGGCCTTTAG 132
GAPDH GGTGTGAACCATGAGAAGTATGA GAGTCCTTCCACGATACCAAAG 123
Therapeutic Advances in Chronic Disease 10
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Statistics
Data are described as means ± SD. Comparison 
between groups were assessed by one-way 
ANOVA by post hoc test using GraphPad Prism 
software v 5.0 (GraphPad Software, San Diego, 
CA, USA). p < 0.05 was considered to be statis-
tically significant.
Results
Melatonin and PAA attenuate IRI-induced renal 
fibrosis and retard the AKI-to-CKD continuum
As shown in Figure 1(a, b), compared with sham 
rats, significant upregulation of α-SMA, collagen 
I and fibronectin expression pointed to marked 
interstitial fibrosis in IRI rats at day 14 after the 
IRI procedure. Following treatment with mela-
tonin and PAA, alpha smooth muscle actin 
(α-SMA) collagen I and fibronectin were reduced 
(compared with IRI rats, p < 0.05). Both mela-
tonin and PAA showed inhibitory effects, while 
the combination of melatonin and PAA per-
formed better than either used alone (p < 0.05). 
Since TGF-β1 plays a central role in fibrogenesis, 
we measured the mRNA and protein expression 
of TGF-β1. As shown in Figure 1(c–e), renal IRI 
resulted in the upregulation of TGF-β1 at both 
mRNA and protein levels (compared with sham 
rats, p < 0.05) from AKI to CKD, while mela-
tonin and PAA suppressed aberrant TGF-β1 
expression. Notably, combined therapy showed a 
stronger inhibitory effect than either compound 
used alone during the AKI-to-CKD continuum 
(p < 0.05).
Melatonin inhibits TGF-β1 pathway while PAA 
selectively suppresses p-Smad3 in renal IRI 
rats
In general, TGF-β1 exerts its profibrotic effect 
through Smad-dependent and Smad-independent 
pathways, which include p38, ERK1/2, and 
PI3K.14 To gain a comprehensive understanding 
of underlying mechanisms of melatonin and PAA, 
we examined the status of both Smad-dependent 
and Smad-independent pathways in IRI rats. As 
shown in Figure 2(a, b), compared with sham 
rats, IRI induced significant upregulation of 
p-Smad2, Smad2, p-Smad3, Smad3, and Smad4, 
and downregulation of Smad7 (p < 0.05), and 
treatment with melatonin prevented this aberrant 
upregulation (p < 0.05). However, treatment 
with PAA selectively inhibited p-Smad3 upregu-
lation (p < 0.05), which indicated different 
mechanisms of melatonin and PAA. Of note, 
PAA showed a stronger inhibitory effect on 
p-Smad3 than melatonin (p < 0.05). As shown 
in Figure 2(c, d), upregulation of p-Smad2 and 
p-Smad3 in the nucleus decreased markedly after 
melatonin and PAA intervention at day 14 after 
the IRI procedure (compared with IRI rats, 
p < 0.05), which is consistent with western blot-
ting results. Although PAA hardly affected 
p-Smad2 expression, PAA could enhance the 
inhibitory effect of melatonin to decrease the 
Table 2. Nucleotide sequences of the primers used for ChIP.
Gene Forward Reverse Product size (bp)
Rat  
Snail CGCTACCGTAGATGGGAATTAG ACTTCATTACTGCTGGGTGTAG 130
Twist ACCTCTTTGAAGCTCTTGGG GGAGATCGCGTGAGTAGTTATG 109
MMP-7 TCTCTCTCTCTCTCTCTCTCTCT GCGAGAGGCCTTAGTTTCTATT 100
PAI-1 CAAGGTGCAGGTCTTGAATTG CTCCTCTCCCTTCTTCCTTCTA 102
Human  
AGT CAGGCTGTGACAGGATGGAA GCTGTTGTCCACCCAGAACT 150
Renin TTGTGGGCATGGGCTTCATT CAATCTGTCCTCCCAGCGAT 150
ACE CCAACCTGCCCCTGGCTAAG GCGAGGAAGCCAGGATGTT 150
AT1R GGAAACAGCTTGGTGGTGAT CCAGCGGTATTCCATAGCTG 150
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expression of p-Smad2 and p-Smad3, indicating 
that supplementation with PAA enhanced the 
inhibitory effects of melatonin.
The Smad-independent pathway was further 
explored. We examined the expression of 
p-ERK1/2, ERK1/2, p-PI3K, PI3K, p-p38, and 
p38, which promoted fibrogenesis.14,38 As shown 
in Figure 2(e, f), compared with sham rats, 
increased levels of p-ERK1/2, ERK1/2, p-PI3K, 
PI3K, p-p38, and p38 were detected in IRI rats 
(p < 0.05). The upregulation of p-ERK1/2, 
ERK1/2, p-PI3K, PI3K, p-p38, and p38 in the 
kidney of IRI rats was significantly inhibited by 
melatonin treatment, while PAA barely reversed 
these abnormalities, indicating entirely different 
mechanisms of melatonin and PAA. Taken 
together, the results indicate that melatonin 
exerted an extensive inhibitory effect on the down-
stream mediators of TGF-β1, while PAA selec-
tively suppressed the upregulation of p-Smad3.
Melatonin ameliorated H/R-induced activation 
of the TGF-β1 pathway while PAA attenuated 
only p-Smad3 expression
To further investigate the underlying mechanism 
of melatonin and PAA in vitro, H/R-induced 
HK-2 cells were employed. As shown in Figure 
3(a–c), compared with the CTL group, upregula-
tion of TGF-β1, p-Smad2, p-Smad3, and Smad4, 
and downregulation of Smad7, was observed 
after H/R stimulation (p < 0.05), indicating acti-
vation of the TGF-β1/Smad pathway. Treatment 
Figure 1. The renoprotective and anti-fibrotic effects of melatonin and PAA. (a, b) Representative micrographs 
of PAS staining, α-SMA, collagen I, and fibronectin protein expression in indicated groups at day 14 after the 
IRI procedure. Scale bar, 25 μm. (c) mRNA level of TGF-β1 in indicated groups. (d, e) Protein level of TGF-β1 in 
indicated groups. Data represented as mean ± SD (n = 7).
IRI, Ischemia-reperfusion injury; PAA, poricoic acid A; PAS, periodic acid–Schiff; α-SMA, alpha smooth muscle actin; TGF-
β1, transforming growth factor-β1.
**p < 0.01 versus sham group; ##p < 0.01 versus IRI group; $p < 0.05; $$p < 0.01 versus IRI + melatonin group; &p < 0.05; 
&&p < 0.01 versus IRI + PAA group.
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with melatonin significantly inhibited the upregu-
lation of p-Smad2, p-Smad3, and Smad4, and 
increased Smad7 expression (compared with the 
H/R group, p < 0.05). Treatment with PAA sup-
pressed only the upregulation of p-Smad3 (com-
pared with the H/R group, p < 0.05), which was 
consistent with the results of IRI rats. As shown 
in Figure 3(c, d), immunofluorescence staining 
indicated that H/R induced p-Smad3 nuclear 
translocation, while melatonin and PAA attenu-
ated this effect in HK-2 cells. Notably, PAA 
exerted a better inhibitory effect than melatonin 
Figure 2. Inhibitory effects of melatonin and PAA against activation of the Smad-dependent and Smad-
independent pathways in vivo. (a, b) Protein levels of p-Smad2, Smad2, p-Smad3, Smad3, Smad4, and Smad7 
in indicated groups. (c, d) Representative micrographs of p-Smad2 and p-Smad3 protein expression in 
indicated groups. Scale bar, 25 μm. (e, f) Protein levels of p-ERK1/2, ERK1/2, p-p38, p38, p-PI3K and PI3K in 
indicated groups. Data represented as mean ± SD (n = 7).
PAA, poricoic acid A.
**p < 0.01 versus sham group; #p < 0.05; ##p < 0.01 versus IRI group; $p < 0.05; $$p < 0.01 versus IRI + melatonin group; 
&p < 0.05; &&p < 0.01 versus IRI + PAA group.
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on Smad3 nuclear translocation (p < 0.05), and 
the combined therapy performed better than 
either compound alone (compared with H/R +  
melatonin or H/R + PAA group, p < 0.05). To 
further confirm the renoprotective role of mela-
tonin and PAA, TGF-β1 was used to stimulate 
HK-2 cell. As shown in Figure S1, TGF-β1 trig-
gered the upregulation of Smad3, but treatment 
with melatonin or PAA significantly inhibited 
this abnormality (compared with H/R group, 
p < 0.05). As shown in Figure 3(e, f), H/R 
resulted in the upregulation of p-ERK1/2, p-p38, 
and p-PI3K in HK-2 cells (compared with CTL 
group, p < 0.05). Melatonin treatment markedly 
suppressed the upregulation of p-ERK1/2, p-p38, 
and p-PI3K, while PAA had no effect on these 
dysregulations (compared with H/R group, 
p < 0.05).
These results point to the conclusion that 
melatonin targets multiple downstream media-
tors of TGF-β1, while PAA selectively inhibits 
Figure 3. The inhibition of melatonin and PAA against the activation of Smad-dependent and Smad-
independent pathways in vivo. (a, b) Protein levels of TGF-β1, p-Smad2, Smad2, p-Smad3, Smad3, Smad4, and 
Smad7 in indicated groups in HK-2 cells. (c, d) Immunofluorescence staining of p-Smad3 (blue) in indicated 
groups. Scale bar, 25 μm. (e, f) Protein levels of p-ERK1/2, ERK1/2, p-p38, p38, p-PI3K, and PI3K in indicated 
groups. Data represented as mean ± SD (n = 6).
H/R, hypoxia/reoxygenation; PAA, poricoic acid A.
**p < 0.01 versus CTL group; #p < 0.05; ##p < 0.01 versus H/R group; $p < 0.05; $$p < 0.01 versus H/R + melatonin group.
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phosphorylation of Smad3, indicating Smad3 as 
the main therapeutic target of PAA.
Smad3 is the main therapeutic target of PAA 
in renal fibrosis while melatonin has multiple 
targets
To further confirm our conclusion that Smad3 is 
the main therapeutic target of PAA, Co-IP and 
RNA interference (RNAi) was employed. As 
shown in Figure 4(a–d), the interactions of Smad2 
or Smad3 with TGFβRI and SARA were observed 
in rats following the IRI procedure (p < 0.05). 
Treatment with melatonin weakened the interac-
tions of Smad2/3 with TGFβRI and SARA in IRI 
rats (compared with IRI group, p < 0.05), while 
PAA selectively affected the interactions of Smad3 
with TGFβRI and SARA. Of note, PAA showed 
a stronger inhibitory effect than melatonin on the 
interactions of Smad3 with TGFβRI and SARA, 
indicating that PAA exerted its antifibrotic effects 
mainly through inhibition of phosphorylation of 
Smad3. The luciferase reporter system containing 
the promoter region of the human collagen I gene 
was employed to detect activity of the Smad3 
promoter. Melatonin and PAA largely mitigated 
H/R-induced Smad3-dependent collagen I pro-
moter activity (Figure 4e).
RNAi was employed to further verify this conclu-
sion. As shown in Figure 4(f, g), specific Smad3 
siRNA significantly inhibited Smad3 protein 
expression (p < 0.05), and melatonin and PAA 
did not affect the process of RNAi. Smad3 siRNA 
also inhibited H/R-induced collagen I and α-SMA 
expression (Figure S2). As shown in Figure 4(h, i), 
after knockdown of Smad3, the protein expression 
of profibrotic vimentin, α-SMA, collagen I, and 
fibronectin were significantly increased in H/R + 
melatonin or H/R + PAA groups (compared with 
H/R group, p < 0.05). Since Smad3 was the ther-
apeutic target of melatonin and PAA, the loss of 
the therapeutic target resulted in partially weak-
ened antifibrotic effects, especially PAA. Notably, 
after knockdown of Smad3, fibronectin protein 
expression was barely reversed after PAA treat-
ment (compared with H/R group, p > 0.05). The 
same results were also observed under TGF-β1 
stimulation (Figure S3). These data support the 
view that Smad3 serves as the main therapeutic 
target of PAA, and the loss of Smad3 partly weak-
ens the antifibrotic effects of PAA and melatonin.
PAA and melatonin inhibit the Wnt/β-catenin 
pathway and profibrotic target genes in renal 
IRI rats
Wnt/β-catenin plays a vital role in the occurrence 
and development of renal disease, especially 
renal fibrosis. We first investigated the mRNA 
expression of several Wnt genes in IRI rats. As 
shown in Figure 5(a, b), a comprehensive survey 
of Wnt genes revealed that several Wnts, includ-
ing Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a, and 
Wnt8a, were markedly upregulated at 3 and 14 
days in IRI rats (compared with sham rats, 
p < 0.05). As shown in Figure 5(c, d), immuno-
histochemical stainings demonstrated that IRI 
caused the upregulation of Wnt1 and β-catenin 
in renal tubules at day 14 after the IRI procedure 
(p < 0.05). Both melatonin and PAA treatment 
significantly improved the upregulation of 
Wnt1 and β-catenin, while combined therapy 
showed a stronger inhibitory effect (compared 
with IRI + melatonin or IRI + PAA group, 
p < 0.05). Figure 5(e, f) shows the increases of 
Wnt1, active β-catenin, and β-catenin, and the 
decrease of nonactive p-β-catenin, which indi-
cates activation of the Wnt/β-catenin pathway in 
IRI rats (compared with sham rats, p < 0.05). 
The inhibitory effect of PAA was stronger than 
that of melatonin on these dysregulations (com-
pared with IRI + melatonin group, p < 0.05). 
Next, we examined downstream targets of the 
Wnt/β-catenin pathway. As shown in Figure 5(g, 
h), the upregulation of snail1, twist, PAI-1, 
and MMP-7 was detected in IRI rats (compared 
with sham rats, p < 0.05). Both melatonin and 
PAA treatment significantly attenuated these 
dysregulations, while treatment with PAA per-
formed better than melatonin (compared with 
IRI + melatonin group, p < 0.05). We further 
verified these results by ChIP assay. As shown in 
Figure 5I, J, IRI activated the β-catenin-mediated 
transcription of snail1, twist, PAI-1, and MMP-7 
at 3 and 14 days in IRI rats (compared with sham 
rats, p < 0.05). Treatment with melatonin and 
PAA significantly reduced the upregulation of 
transcription, while combined therapy showed 
stronger inhibitory effects than each compound 
used alone (compared with IRI + melatonin or 
IRI + PAA group, p < 0.05). Additionally, the 
inhibitory effects of PAA were stronger than 
those of melatonin (compared with IRI + mela-
tonin group, p < 0.05). Taken together, mela-
tonin and PAA treatment simultaneously 
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Figure 4. Interference effects of melatonin and PAA on Smad2/3 phosphorylation. (a, b) Co-IP bands of 
Smad2 and Smad3 in indicated groups. (c, d) Co-IP bands of Smad2 and Smad3 in indicated groups. (e) 
Luciferase activity in indicated groups after cotransfected with p(CACA)-luciferase plasmid and PGL3. (f) 
Protein level of Smad3 in indicated groups. (g) Protein level of Smad3 in indicated groups. (h, i) Protein 
levels of vimentin, α-SMA, collagen I, and fibronectin in indicated groups. Data represented as mean ± SD 
(n = 6).
Co-IP, Coimmunoprecipitation; PAA, poricoic acid A; α-SMA, alpha smooth muscle actin.
**p < 0.01 versus CTL or sham group; #p < 0.05; ##p < 0.01 versus H/R or IRI group; $p < 0.05; $$p < 0.01 versus 
IRI + melatonin or H/R + melatonin group; &p < 0.05; &&p < 0.01 versus H/R + PAA group.
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Figure 5. Inhibitory effect of melatonin and PAA on the activation of the Wnt/β-catenin pathway in vivo. (a) The 
mRNA levels of Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a, and Wnt8a in different groups (3 days after IRI procedure).  
(b) The mRNA levels of Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a, and Wnt8a in different groups (14 days after IRI 
procedure). (c, d) Representative micrographs of Wnt1 and β-catenin protein expression in indicated groups at 
day 14 after IRI procedure. Scale bar, 25 μm. (e, f) Protein levels of Wnt1, active β-catenin, p-β-catenin, and  
β-catenin in indicated groups. (g, h) Protein levels of snail1, twist, MMP-7, and PAI-1 in indicated groups.  
(i) ChIP assay results of snail1, twist, MMP-7, and PAI-1 in different groups (3 days after IRI procedure).  
(j) ChIP assay results of snail1, twist, MMP-7, and PAI-1 in different groups (14 days after IRI procedure). Data 
represented as mean ± SD (n = 7).
ChIP, chromatin immunoprecipitation; MMP-7, matrix metalloproteinase-7; PAA, poricoic acid A; PAI-1, plasminogen 
activator inhibitor-1.
**p < 0.01 versus sham group; #p < 0.05; ##p < 0.01 versus IRI group; $p < 0.05; $$p < 0.01 versus IRI + melatonin group; 
&p < 0.05; &&p < 0.01 versus IRI + PAA group.
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retarded the activation of Wnt/β-catenin and 
downstream target expression, while PAA had a 
larger inhibitory effect than melatonin.
Combined therapy inhibits the Wnt/β-catenin 
pathway and mediates transcription of RAS 
components
To further confirm the inhibitory effects of 
melatonin and PAA treatment on the activation 
of Wnt/β-catenin signaling, H/R-induced HK-2 
cells were employed. As shown in Figure 6(a), 
increases in Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a, 
and Wnt8a were detected after H/R stimulation 
(compared with CTL group, p < 0.05). 
Compared with the H/R group, melatonin and 
PAA treatment significantly mitigated this 
mRNAs dysregulation (p < 0.05). As shown in 
Figure 6(b–e), the upregulation of Wnt1, active 
β-catenin, snail1, twist, PAI-1, and MMP-7, 
and downregulation of p-β-catenin induced by 
H/R stimulation were significantly improved by 
melatonin and PAA treatment, and PAA had 
greater inhibitory effects than melatonin (com-
pared with H/R + melatonin group, p < 0.05). 
Additionally, melatonin and PAA also inhibited 
activation of the Wnt/β-catenin pathway under 
conditions of Wnt1 overexpression (Figure S4), 
which further confirmed the inhibitory effects 
of melatonin and PAA against Wnt/β-catenin 
activity. RAS components are also downstream 
targets of the Wnt/β-catenin signaling that 
induces fibrosis.19 We further examined β-
catenin-mediated AGT, renin, ACE, and AT1R 
transcription. Compared with the CTL group, 
H/R stimulation increased β-catenin-mediated 
transcriptions of AGT, renin, ACE, and AT1R 
in HK-2 cells (p < 0.05). Both melatonin and 
PAA treatment inhibited the effects of β-catenin 
on the transcriptional activity of these genes, 
while combined therapy resulted in stronger 
inhibitory effects.
PAA exhibits stronger inhibitory effects than 
melatonin against the interaction of Wnt/β-
catenin and TGF-β/Smad pathway
As shown in Figure 7(a, b), IRI induced the 
interaction of Smad2 and Smad3 with β-
catenin at day 14 after the IRI procedure (com-
pared with sham group, p < 0.05). Melatonin 
treatment disturbed the interaction of Smad2 
and Smad3 with β-catenin, while PAA 
selectively inhibited the interaction of Smad3 
with β-catenin. Notably, combined therapy 
exhibited stronger effects against the interac-
tion of Smad2 and Smad3 with β-catenin. The 
same results were observed in H/R-induced 
HK-2 cells (Figure 7c, d). Inhibition of the 
interaction of Smad2 and Smad3 with β-
catenin may be one of the reasons for the anti-
fibrotic effects of melatonin and PAA.
Discussion
Ischemic kidney injury is the critical cause of AKI 
in hospitalized patients, and is related to high 
morbidity and mortality rates. Incomplete recov-
ery from AKI is a well-recognized pathway to pro-
gressive CKD.2 AKI can cause CKD directly, 
and increase the risk of developing incident 
ESRD. Renal IRI is the common cause that trig-
gers the AKI-to-CKD continuum. Knowledge of 
the molecular mechanisms of the AKI-to-CKD 
continuum has been partly revealed,2 but few 
pharmacological approaches effectively prevent 
it. AKI induces impairments in tubular cells that 
generate massive production of profibrotic 
cytokines, including TGF-β1 and β-catenin, and 
these mediators result in the EMT and excessive 
ECM production that eventually causes renal 
fibrosis.1 Among profibrotic cytokines, TGF-β1 
plays a central role in fibrogenesis. Additionally, 
the persistent activation of Wnt/β-catenin signal-
ing promotes AKI to progressive CKD.7 Hence, 
the inhibition of TGF-β and Wnt/β-catenin sign-
aling is beneficial to retard the IRI-induced AKI-
to-CKD continuum.
TGF-β1 can drive EMT of several types of cells, 
promote excessive ECM production, and inhibit 
ECM degradation suppression.39 The TGF-β 
pathway currently divides into a Smad-
dependent and a Smad-independent pathway. 
In the TGF-β/Smad pathway, active TGF-β1 
binds to TGFβRII, then recruits TGFβRI and 
phosphorylates downstream Smad2 and Smad3, 
which are extensively activated in the fibrotic 
kidney with CKD.40 Within the Smads family, 
Smad3 plays a decisive role due to direct binding 
to the promoter region of collagens to trigger 
their production.1 Smad4 participates in the 
nucleocytoplasmic shuttling of Smad2/3 com-
plexes, while Smad7 is a negative regulator of 
the TGF-β/Smad pathway. Smad3 directly 
induces Smad7 production, while Smad7 
Therapeutic Advances in Chronic Disease 10
14 journals.sagepub.com/home/taj
Figure 6. Inhibitory effect of melatonin and PAA against the activation of Wnt/β-catenin pathway in vitro. (a) 
The mRNA levels of Wnt1, Wnt2, Wnt3, Wnt3a, Wnt7a, and Wnt8a in different groups. (b, c) Protein levels of 
Wnt1, active β-catenin, p-β-catenin, and β-catenin in indicated groups. (d, e) Immunofluorescence staining of 
Wnt1 (yellow) and active β-catenin (green) in indicated groups. Scale bar, 25 μm. (f, g) Protein levels of snail1, 
twist, MMP-7 and PAI-1 in indicated groups. (h) ChIP assay results of AGT, renin, ACE and AT1R in different 
groups. Data represented as mean ± SD (n = 6).
ACE, Angiotensin-converting enzyme; AGT angiotensinogen, AT1R, angiotensin II type 1 receptor; ChIP, chromatin 
immunoprecipitation; MMP-7, matrix metalloproteinase-7; PAA, poricoic acid A; PAI-1, plasminogen activator inhibitor-1.
**p < 0.01 versus CTL; #p < 0.05; ##p < 0.01 versus H/R group; $p < 0.05; $$p < 0.01 versus H/R + melatonin group; 
&p < 0.05; &&p < 0.01 versus H/R + PAA group.
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contributes to the degradation of Smad3.14 In 
this study, renal IRI significantly induced the 
upregulation of TGF-β1 at both mRNA and 
protein levels during the AKI-to-CKD contin-
uum. The increase of TGF-β1 resulted in the 
upregulation of p-Smad2, p-Smad3, and Smad4, 
as well as the downregulation of Smad7. 
Treatment with melatonin significantly reduced 
the upregulation of p-Smad2, p-Smad3, and 
Smad4, as well as increasing Smad7 expression. 
However, PAA showed different inhibitory 
effects from melateonin. PAA selectively inhib-
ited the phosphorylation of Smad3 but did not 
affect other mediators. Similar results were 
observed from H/R and TGF-β1-induced HK-2 
cells. Co-IP data also demonstrated that mela-
tonin blocked the interactions of Smad2 and 
Smad3 with TGFβRI and SARA, while PAA 
specifically suppressed the interactions of Smad3 
with TGFβRI and SARA, and PAA had a greater 
inhibitory effect than melatonin on the phospho-
rylation of Smad3. After knockdown of Smad3, 
the effects of PAA and melatonin were signifi-
cantly weakened, partially owing to the loss of 
their therapeutic targets. Promoter assay results 
indicated that both melatonin and PAA miti-
gated IRI-induced Smad3-dependent collagen I 
promoter activity, while PAA showed a stronger 
inhibitory effect than melatonin. Taken together, 
melatonin showed extensive inhibitory effects on 
Smad signaling, while PAA selectively sup-
pressed the phosphorylation of Smad3 and had a 
greater inhibitory effect than melatonin on 
p-Smad3.
The Smad-independent pathway was examined 
further. IRI and H/R led to the upregulation of 
p-PI3K, p-ERK1/2, and p-p38. Melatonin sig-
nificantly reduced the upregulation of p-PI3K, 
p-ERK1/2, and p-p38, while PAA hardly affected 
these downstream mediators during the AKI-to-
CKD continuum. Although both melatonin and 
PAA treatment exhibited good renoprotective 
and antifibrotic effects, the underlying mecha-
nisms of these two agents were totally different. 
Melatonin could simultaneously target multiple 
downstream mediators of TGF-β1 to reduce 
fibrogenesis, while PAA performed an entirely 
different mechanism that selectively inhibited the 
phosphorylation of Smad3.
Figure 7. PAA enhanced the effect of melatonin on the interaction of Smad3 and β-catenin signaling. (a, b) 
Co-IP bands of Smad2 and Smad3 in indicated groups at day 14 after the IRI procedure. (c, d) Co-IP bands of 
Smad2 and Smad3 in indicated groups. Data represented as mean ± SD (n = 6).
Co-IP, Coimmunoprecipitation; IRI, ischemia-reperfusion injury; PAA, poricoic acid A.
**p < 0.01 versus CTL; #p < 0.05; ##p < 0.01 versus H/R group; $p < 0.05; $$p < 0.01 versus IRI + melatonin or 
H/R + melatonin group; &p < 0.05; &&p < 0.01 versus H/R + PAA group.
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In normal adult kidney, Wnt/β-catenin is silent. 
Once the kidney suffers injury, Wnt/β-catenin 
signaling is activated and induces the upregulation 
of downstream targets, most of which are associ-
ated with fibrogenesis.20 The level of β-catenin 
controls both activation of this pathway and 
downstream gene expression.41 In the absence of 
Wnt ligands, β-catenin is phosphorylated and 
subsequently degraded by the proteasome. In the 
presence of Wnts, the degradation of β-catenin is 
inhibited, resulting in β-catenin dephosphoryla-
tion and stabilization. β-Catenin accumulates in 
the cytoplasm and transfers into the nucleus,42 
which initiates transcription of target genes, 
including snail1, twist, PAI-1, and MMP–7. 
Snail1 and twist promote fibrogenesis in the kid-
ney.43 Snail1 expression reduces E-cadherin 
expression and further disrupts cell-to-cell adhe-
sion in epithelial cells, which is the initiation of 
EMT.44 PAI-1 contributes to CKD progress.18 
The upregulation of MMP-7 results in the shed-
ding of E-cadherin and promotes cell apoptosis 
and death.45 The expression of several Wnts were 
upregulated at 3 and 14 days in IRI rats, which 
was accompanied by upregulation of active β-
catenin and downregulation of p-β-catenin pro-
tein, indicating activation of the Wnt/β-catenin 
pathway during the AKI-to-CKD continuum. 
Activation of the Wnt/β-catenin pathway resulted 
in upregulation of snail1, twist, PAI-1, and 
MMP-7 in IRI rats and H/R-induced HK-2 cells. 
Melatonin and PAA reduced the upregulation of 
Wnt1 and active β-catenin, and restored the 
downregulation of p-β-catenin during the AKI-to-
CKD continuum. The upregulation of snail1, 
twist, PAI-1, and MMP-7 were also attenuated by 
melatonin and PAA treatment. Melatonin and 
PAA transcriptionally suppressed expression of 
snail1, twist, PAI-1, and MMP–7. Inhibition of 
the Wnt/β-catenin pathway by melatonin and 
PAA also retarded the expression of RAS compo-
nents. Although both melatonin and PAA inhib-
ited the Wnt/β-catenin pathway, PAA showed a 
stronger inhibitory effect than melatonin during 
the AKI-to-CKD continuum.
Additionally, the interaction exists in TGF-β/
Smad and Wnt/β-catenin pathways. TGF-β1 
contributes to β-catenin accumulation in the cyto-
plasm and the combination with TCF/LEF in the 
nucleus to initiate the expression of profibrotic 
factors and induce fibrosis.46 TGF-β1 also induces 
β-catenin/Smad3 complex to enhance Smad3-
induced fibrosis.47 Inhibition of the β-catenin/
Smad3 complex weakens TGF-β-induced 
fibrosis.47 In this study, we found that IRI and 
H/R enhanced the interaction of Smad2/3 and 
β-catenin, which accelerated renal fibrosis. 
Melatonin disturbed the interactions of Smad2 
and Smad3 with β-catenin, while PAA selectively 
affected the interaction of Smad3 with β-catenin. 
Notably, PAA enhanced melatonin’s effects to 
inhibit the interaction of Smad2 and β-catenin, 
while melatonin enhanced the effects of PAA in 
inhibiting the interaction of Smad3 and β-catenin. 
These results point to the synergetic effects under-
lying the mechanisms of PAA and melatonin 
against renal fibrosis (Figure 8). Both melatonin 
and PAA have the potential to be developed as 
new agents against renal fibrosis.
Our current study has several limitations. Here, 
we found that CKD contributed to the interac-
tion of Smad3 and β-catenin during the AKI-to-
CKD continuum, and melatonin and PAA 
treatment significantly weakened this interaction. 
However, the inhibitory effects of combined mel-
atonin and PAA therapy against other profibrotic 
signal pathways, including interleukin, hedgehog, 
and the connective tissue growth factor pathway, 
were not detected, which may suggest their 
involvement in the therapeutic effects of com-
bined therapy. Additionally, a mouse model was 
not used. However, the positive results from the 
human cell line and rat model suggested possible 
generalization of renoprotection by melatonin 
and PAA in different species.
In conclusion, our study demonstrated that com-
bined therapy with melatonin and PAA led to bet-
ter antifibrotic effects than either compound used 
alone in renal IRI rats and H/R-induced HK-2 
cells. Melatonin and PAA could prevent the AKI-
to-CKD continuum by inhibition of the TGF-β/
Smad and Wnt/β-catenin pathways. However, 
their underlying mechanisms were different. 
Melatonin exhibited extensive inhibitory effects, 
while PAA selectively inhibited the phosphoryla-
tion of Smad3. Melatonin and PAA treatment also 
disturbed the interaction of the TGF-β/Smad and 
Wnt/β-catenin pathways. These results strongly 
support the effects of melatonin and PAA against 
renal fibrosis, and provide a candidate strategy to 
slow down the AKI-to-CKD continuum.
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